Chronic Kidney Disease

The European Medicines Agency has accepted a marketing authorization application from Astellas Pharmaceuticals for its hypoxia-inducible factor prolyl hydroxylase inhibitor roxadustat for the treatment of anemia in adult patients with chronic kidney disease.

The COVID-19 virus has tested the world’s population and economy, leading to changes in the way we deal with all aspects of life. The idea of months ahead of social distancing, mask wearing, high unemployment, business closures, new rules for eating in restaurants and limited attendance at concerts and sporting events does not bode well.

Adults with type 2 diabetes and a low estimated glomerular filtration rate must be more aggressively managed with tailored treatment options to preserve kidney function and reduce morbidity and mortality risk.

Chronic kidney disease was present in more than 20% of patients who died of COVID-19 in Italy, according to researchers who presented data at the virtual ERA-EDTA Congress.

Pharmaceutical company AstraZeneca has donated $1.1 million to the American Kidney Fund’s coronavirus emergency relief program, allowing for all patients currently on the waitlist to receive financial assistance.

Patients with chronic kidney disease and hypertension who underwent intensive blood pressure lowering had increases in fibroblast growth factor 23 levels regardless of changes in eGFR, according to a published study.

A ready-to-drink solution of sodium picosulfate, magnesium oxide and citric acid had similar efficacy as a bowel preparation among patients with normal and impaired renal function, according to research from Digestive Disease Week.

A published study suggests increasing access to health care could help improve blood pressure control for Hispanic patients — a population found to have low control rates — thereby reducing the risk for subsequent development or progression of chronic kidney disease.

Higher serum uromodulin was associated with a lower risk for all-cause mortality and kidney failure in white patients with chronic kidney disease, according to findings from a published study.

Obtaining research kidney biopsy cores in patients with diabetes was safe with no clear evidence of a negative impact, according to findings from a recently published study.